Acumen Pharmaceuticals (ABOS) Net Income towards Common Stockholders (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 26.86% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$112.8 million (up 3.41% YoY), and the FY2025 full-year result was -$201.9 million, down 29.31% from the prior year.
• Net Income towards Common Stockholders improved to -$21.2 million in Q1 2026, from -$25.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.2 million in Q1 2022 to a low of -$51.2 million in Q3 2022.
• A 5-year average of -$23.2 million and a median of -$21.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 1205.51% in 2022 and surged 74.77% in 2023, its largest moves.
• Tracing ABOS's Net Income towards Common Stockholders over 5 years: stood at -$14.1 million in 2022, then slipped by 4.03% to -$14.7 million in 2023, then tumbled by 148.55% to -$36.5 million in 2024, then soared by 31.69% to -$25.0 million in 2025, then advanced by 15.26% to -$21.2 million in 2026.
• Business Quant data shows ABOS's Net Income towards Common Stockholders at -$21.2 million in Q1 2026, -$25.0 million in Q4 2025, and -$25.9 million in Q3 2025.